Point72 Hong Kong’s Royalty Pharma RPRX Stock Holding History

Point72 Hong Kong’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,789	Closed	-$814K	–	685
2024 Q1	$814K	Sell	26,789 -87,836	-77%	-$2.59M	0.04%	294
2023 Q4	$3.22M	Buy	+114,625	New	+$3.15M	0.19%	144
2022 Q1	–	Sell	-6,480	Closed	-$258K	–	2263
2021 Q4	$258K	Buy	+6,480	New	+$252K	0.01%	946
2021 Q3	–	Sell	-5,377	Closed	-$220K	–	2374
2021 Q2	$220K	Buy	+5,377	New	+$229K	0.01%	1134
2020 Q3	–	Sell	-37,659	Closed	-$1.83M	–	1485
2020 Q2	$1.83M	Buy	+37,659	New	+$1.86M	0.2%	127

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Point72 Hong Kong's RPRX Position: Q2 2024 in Review

Point72 Hong Kong sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 26,789 shares — an estimated $814K sold.

Point72 Hong Kong first reported a position in RPRX in Q2 2020 and held it in 5 quarters. The position peaked at $3.22M in Q4 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

Point72 Hong Kong reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
Point72 Hong Kong sold 26,789 Royalty Pharma shares in Q2 2024, an estimated $814K.
Point72 Hong Kong first reported a position in Royalty Pharma in Q2 2020 and held it in 5 quarters.
Point72 Hong Kong's Royalty Pharma position peaked at $3.22M in Q4 2023.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Point72 Hong Kong's 13F filing for Q2 2024, filed 14 Aug 2024.